HK Stock Market Move | MIRXES-B (02629) rose nearly 8% in the early session, working together with Watson to develop the ASEAN market, and jointly building an innovative RNA precision medical system.

MIRXES-B(02629) rose nearly 8% in early trading, up 2.48% at the time of writing, trading at 53.8 Hong Kong dollars, with a turnover of 182.942 million Hong Kong dollars. On the news front, on November 18, Mirxes announced that it had officially signed a memorandum of understanding with Walvax Biotechnology (300142.SZ). The two parties will deepen their cooperation in the fields of molecular diagnostics and vaccine research, and jointly expand the ASEAN and global markets. This cooperation marks the strategic synergy between a leading precision diagnostics company and a top vaccine research company, laying a solid foundation for building a prevention and precision medical platform with RNA as its core. It is worth noting that in October this year, the core product GASTROClear was approved for listing by the National Medical Products Administration (NMPA) of China, becoming the world's first and currently only molecular diagnostic IVD product approved for gastric cancer screening. Founder released a research report stating that this milestone event not only achieved the company's commercial breakthrough from "0 to 1", but also brought a new logic for value reevaluation. This approval means that the company has officially entered the vast Chinese gastric cancer screening market, becoming the most important performance catalyst in the short term.